Patents Assigned to TAKEDA VACCINES, INC.
-
Patent number: 10632184Abstract: Embodiments herein relate to compositions and methods for stabilizing live alphaviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated alphaviruses. Certain embodiments relate to providing a stabilizing composition while reducing immune reaction in a subject to excipients that stabilize the live alphaviruses by providing improved formulations. Yet other embodiments relate to uses of compositions disclosed herein in kits for portable applications and methods wherein the compositions reduce degradation of the live alphaviruses.Type: GrantFiled: March 27, 2017Date of Patent: April 28, 2020Assignee: TAKEDA VACCINES, INC.Inventors: Jill Ann Livengood, Timothy Duane Powell
-
Patent number: 10525120Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.Type: GrantFiled: July 22, 2016Date of Patent: January 7, 2020Assignee: TAKEDA VACCINES, INC.Inventors: Dan Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
-
Patent number: 10512682Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.Type: GrantFiled: May 31, 2018Date of Patent: December 24, 2019Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
-
Patent number: 10501500Abstract: The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.Type: GrantFiled: October 3, 2014Date of Patent: December 10, 2019Assignee: Takeda Vaccines, Inc.Inventor: Joel Haynes
-
Patent number: 10449231Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: April 20, 2017Date of Patent: October 22, 2019Assignees: TAKEDA VACCINES, INC., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
-
Publication number: 20190194628Abstract: The present disclosure relates to methods of producing Enterovirus C, e.g., for poliomyelitis vaccine production. In some embodiments, the methods include adding polysorbate to the cell culture medium during or prior to inoculation with the virus and/or culturing cells in a fixed bed bioreactor. Further provided herein is an Enterovirus C produced by the methods of production disclosed herein, as well as compositions, immunogenic compositions, and vaccines related thereto.Type: ApplicationFiled: September 1, 2017Publication date: June 27, 2019Applicants: Takeda Vaccines, Inc., Takeda Pharmaceutical Company LimitedInventors: Raman RAO, Tatsuki SATO, Kaori ODA, Kuniaki NAKAMURA, Takeshi NISHIHAMA
-
Publication number: 20190111124Abstract: Embodiments herein relate to compositions and methods for stabilizing live alphaviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated alphaviruses. Certain embodiments relate to providing a stabilizing composition while reducing immune reaction in a subject to excipients that stabilize the live alphaviruses by providing improved formulations. Yet other embodiments relate to uses of compositions disclosed herein in kits for portable applications and methods wherein the compositions reduce degradation of the live alphaviruses.Type: ApplicationFiled: March 27, 2017Publication date: April 18, 2019Applicant: Takeda Vaccines, Inc.Inventors: Jill Ann Livengood, Timothy Duane Powell
-
Publication number: 20190106682Abstract: Embodiments herein relate to live, attenuated alphaviruses that are incapable of replicating in mosquito cells and of transmission by mosquito vectors. Other embodiments concern methods of generating live, attenuated alphaviruses, constructs thereof and uses of these live, attenuated alphaviruses in immunogenic compositions. Other embodiments relate to pharmaceutical compositions including the live, attenuated alphaviruses and methods for manufacturing these live, attenuated viruses. Yet other embodiments relate to uses of these compositions in kits for portable applications such as vaccines against alphavirus infection and methods thereof.Type: ApplicationFiled: March 28, 2017Publication date: April 11, 2019Applicant: Takeda Vaccines, Inc.Inventors: Jill Ann Livengood, Timothy Duane Powell
-
Patent number: 10233429Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.Type: GrantFiled: October 27, 2017Date of Patent: March 19, 2019Assignee: Takeda Vaccines, Inc.Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
-
Patent number: 10172930Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.Type: GrantFiled: May 2, 2016Date of Patent: January 8, 2019Assignee: TAKEDA VACCINES, INC.Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
-
Patent number: 10167320Abstract: Methods of purifying virus-like particles (VLPs) that are substantially free of process contaminants and infectious agents. The methods incorporate, for example, low-pH treatment during harvest and/or inactivation by a solvent and/or detergent during VLP capture.Type: GrantFiled: June 24, 2013Date of Patent: January 1, 2019Assignee: Takeda Vaccines, Inc.Inventor: Ross Taylor
-
Patent number: 10137186Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.Type: GrantFiled: March 13, 2014Date of Patent: November 27, 2018Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
-
Patent number: 10130696Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.Type: GrantFiled: September 18, 2008Date of Patent: November 20, 2018Assignee: TAKEDA VACCINES, INC.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
-
Patent number: 10052374Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: GrantFiled: June 28, 2016Date of Patent: August 21, 2018Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Publication number: 20180195048Abstract: The present disclosure relates to methods of producing Enterovirus A, e.g., for vaccine production, that include culturing cells in a fixed bed bioreactor. Further provided herein is an Enterovirus A produced by the methods of production disclosed herein, as well as compositions, immunogenic compositions, and vaccines related thereto.Type: ApplicationFiled: February 12, 2016Publication date: July 12, 2018Applicant: Takeda Vaccines, Inc.Inventor: Raman RAO
-
Publication number: 20180187165Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.Type: ApplicationFiled: October 27, 2017Publication date: July 5, 2018Applicant: Takeda Vaccines, Inc.Inventors: Subash Chandra DAS, Joseph David SANTANGELO, Dan Thomas STINCHCOMB, Jorge E. OSORIO
-
Patent number: 10010599Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.Type: GrantFiled: March 15, 2013Date of Patent: July 3, 2018Assignee: TAKEDA VACCINES, INC.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
-
Patent number: 10010600Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.Type: GrantFiled: November 6, 2015Date of Patent: July 3, 2018Assignee: TAKEDA VACCINES, INC.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
-
Publication number: 20180125965Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof. Thus, there is a need to develop vaccines and immunogenic compositions for treating and/or preventing hand, food, and mouth disease, particularly in children. In order to meet this need, the present disclosure provides vaccines and immunogenic compositions for treating and/or preventing hand, foot, and mouth disease that include antigens from at least one virus that causes hand, foot, and mouth disease in humans, such as EV71, CA6, and CA16.Type: ApplicationFiled: November 6, 2015Publication date: May 10, 2018Applicant: Takeda Vaccines, Inc.Inventors: Subash Chandra DAS, Joseph David SANTANGELO, Dan Thomas STINCHCOMB, Jorge E. OSORIO
-
Patent number: 9890362Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally relate to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.Type: GrantFiled: September 19, 2014Date of Patent: February 13, 2018Assignee: Takeda Vaccines, Inc.Inventors: Dan T Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio